Biogen’s Aduhelm: Slow to Launch with Controversy Continuing

Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow. Bickering still continues over the drug’s efficacy, the approval process, its cost, whether the company’s ties with the U.S. Food and Drug Administration (FDA) were inappropriate, and if and how Medicare and insurers will pay for it.